top of page

Dr. Brad Nelson

C3 IMPACT-PRO

Scientific Co-Director, Immunotherapy Program

BC Cancer

Professor of Biochemistry/Microbiology 

University of Victoria

Professor of Medical Genetics

University of British Columbia

Dr. Nelson received training at the University of California at Berkeley (Ph.D.) and Fred Hutchinson Cancer Research Center (postdoc), and in 2003 became founding Director of the Deeley Research Centre.  His laboratory is pursuing the development of innovative immunotherapies for cancer.  Areas of focus include: understanding how tumour-reactive T cells and B cells promote survival of cancer patients; using genomic and bioinformatic methods to decipher the barriers to effective immunotherapy; and using the power of genetic engineering to create more precise and potent immune cells for use in immunotherapy. 

Dr. Brad Nelson
  • Instagram
  • Facebook
  • Twitter
logoImage.png
leaf-cihr-colour-en_edited.png

Le Collectif Canadien pour le cholangiocarcinome (C3) est financé par une subvention d'équipe révolutionnaire de la Société Canadienne du cancer en partenariat avec les Instituts de recherche en santé du Canada. Les fonds de la subvention pour le C3 sont gérés par l'Institut de recherche de l'Hôpital d'Ottawa, qui sert d'institut principal pour toutes les opérations collaboratives.

© 2025 www.cholangio.ca. All rights reserved.

bottom of page